Kapil Saxena

3.1k total citations · 2 hit papers
39 papers, 1.2k citations indexed

About

Kapil Saxena is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kapil Saxena has authored 39 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 17 papers in Hematology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kapil Saxena's work include HER2/EGFR in Cancer Research (13 papers), Hemophilia Treatment and Research (8 papers) and Acute Myeloid Leukemia Research (7 papers). Kapil Saxena is often cited by papers focused on HER2/EGFR in Cancer Research (13 papers), Hemophilia Treatment and Research (8 papers) and Acute Myeloid Leukemia Research (7 papers). Kapil Saxena collaborates with scholars based in United States, Japan and Spain. Kapil Saxena's co-authors include Sue E. Crawford, Umesh C. Karandikar, Nicholas C. Zachos, Xi-Lei Zeng, Sarah E. Blutt, Mary K. Estes, Khalil Ettayebi, Margaret E. Conner, Olga Kovbasnjuk and Narayan P. Sastri and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Nature Communications.

In The Last Decade

Kapil Saxena

38 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human Intestinal Enteroids: a New Model To Study Human Rotavirus Infection, Host Restriction, and Pathophysiology

2015 285 citations Kapil Saxena, Sarah E. Blutt et al. profile →
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

2023 96 citations Takayuki Yoshino, Maria Di Bartolomeo et al. Nature Communications profile →

Peers

Countries citing papers authored by Kapil Saxena

Since Specialization

Citations

This map shows the geographic impact of Kapil Saxena's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kapil Saxena with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kapil Saxena more than expected).

Fields of papers citing papers by Kapil Saxena

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kapil Saxena. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kapil Saxena. The network helps show where Kapil Saxena may publish in the future.

Co-authorship network of co-authors of Kapil Saxena

This figure shows the co-authorship network connecting the top 25 collaborators of Kapil Saxena. A scholar is included among the top collaborators of Kapil Saxena based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kapil Saxena. Kapil Saxena is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	BH3 mimetics augment cytotoxic T cell killing of acute myeloid leukemia via mitochondrial apoptotic mechanism 2025 ·Cell Death Discovery ·Kapil Saxena, (unknown), (unknown), Shailbala Singh, Qi Zhang, Zhihong Zeng, (unknown), Marina Konopleva, Cassian Yee	5
2	Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer breakdown → 2023 ·Nature Communications ·Takayuki Yoshino, Maria Di Bartolomeo, Kanwal Raghav, Toshiki Masuishi, Fotios Loupakis, Hisato Kawakami, Kensei Yamaguchi, Tomohiro Nishina, Zev A. Wainberg, Élena Elez, J. Rodríguez, Marwan Fakih, Fortunato Ciardiello, Kapil Saxena, Kojiro Kobayashi, Emarjola Bako, Yasuyuki Okuda, Gerold Meinhardt, Axel Grothey, Salvatore Siena, (unknown), (unknown)	96
3	976P Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01 2022 ·Annals of Oncology ·Bob T. Li, Egbert F. Smit, (unknown), Kazuhiko Nakagawa, Kōichi Goto, Julien Mazières, Dipesh Uprety, Lyudmila Bazhenova, Andreas Saltos, Enriqueta Felip, (unknown), M. Pérol, L. Paz-Ares, Kapil Saxena, Ryota Shiga, Yun Cheng, (unknown), David Planchard, Pasi A. Jänne	4
4	A phase 1b/2 study of azacitidine with PD‐L1 antibody avelumab in relapsed/refractory acute myeloid leukemia 2021 ·Cancer ·Kapil Saxena, Shelley M. Herbrich, Naveen Pemmaraju, Tapan M. Kadia, Courtney D. DiNardo, Gautam Borthakur, Sherry Pierce, Elias Jabbour, Sa A. Wang, Carlos E. Bueso‐Ramos, Sanam Loghavi, Guilin Tang, (unknown), (unknown), Steven M. Kornblau, Michael Andreeff, Guillermo Garcia‐Manero, Farhad Ravandi, Marina Konopleva, Naval Daver	47
5	1361TiP Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02) 2021 ·Annals of Oncology ·Egbert F. Smit, B.T. Li, Julien Mazières, David Planchard, Kazuhiko Nakagawa, Kōichi Goto, Luis Paz‐Ares, Silvia Novello, (unknown), M-J. Ahn, (unknown), Kenneth J. O’Byrne, Mehreteab Aregay, Ryota Shiga, Kapil Saxena, Gudrun Meinhardt, Pasi A. Jänne	1
6	Impact of frontline treatment approach on outcomes of myeloid blast phase CML 2021 ·Journal of Hematology & Oncology ·Kapil Saxena, Elias Jabbour, Ghayas C. Issa, Koji Sasaki, Farhad Ravandi, Abhishek Maiti, Naval Daver, Tapan M. Kadia, Courtney D. DiNardo, Marina Konopleva, Jörge E. Cortes, Musa Yılmaz, Kelly S. Chien, Sherry Pierce, Hagop M. Kantarjian, Nicholas J. Short	24
7	New Treatment Options for Older Patients with Acute Myeloid Leukemia 2021 ·Current Treatment Options in Oncology ·Kapil Saxena, Marina Konopleva	10
8	LBA45 Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC) 2021 ·Annals of Oncology ·B.T. Li, Egbert F. Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazières, Misako Nagasaka, Lyudmila Bazhenova, Andreas Saltos, Enriqueta Felip, (unknown), M. Pérol, Luis Paz‐Ares, Kapil Saxena, Ryota Shiga, Yun Cheng, Suddhasatta Acharyya, Javad Shahidi, David Planchard, Pasi A. Jänne	3
9	SOHO State of the Art Updates and Next Questions: Harnessing Apoptosis in AML 2021 ·Clinical Lymphoma Myeloma & Leukemia ·Kapil Saxena, Courtney D. DiNardo, Naval Daver, Marina Konopleva	5
10	Harnessing Apoptosis in AML 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Kapil Saxena, Courtney D. DiNardo, Naval Daver, Marina Konopleva	5
11	84MO A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01 2020 ·Annals of Oncology ·Takayuki Yoshino, Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav, Toshiki Masuishi, Fotios Loupakis, Hisato Kawakami, Kensei Yamaguchi, Tomohiro Nishina, Marwan Fakih, Élena Elez, J. Rodríguez, Fortunato Ciardiello, Kapil Saxena, (unknown), Ken Kobayashi, Emarjola Bako, Yasuyuki Okuda, Axel Grothey	1
12	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01. 2020 ·Journal of Clinical Oncology ·Egbert F. Smit, Kazuhiko Nakagawa, Misako Nagasaka, Enriqueta Felip, Yasushi Goto, Bob T. Li, Jose M. Pacheco, Haruyasu Murakami, Fabrice Barlési, Andreas Saltos, M. Pérol, Hibiki Udagawa, Kapil Saxena, Ryota Shiga, (unknown), Suddhasatta Acharyya, Javad Shahidi, David Planchard, Pasi A. Jänne	94
13	An expert overview of emerging therapies for acute myeloid leukemia: novel small molecules targeting apoptosis, p53, transcriptional regulation and metabolism 2020 ·Expert Opinion on Investigational Drugs ·Kapil Saxena, Marina Konopleva	9
14	Bay 81-8973 Prophylaxis Frequency and Long-Term Bleed Outcomes in the Leopold I Extension Study 2017 ·Blood ·Kapil Saxena, Gautam Sajeev, Rajeev Ayyagari, (unknown), (unknown), (unknown), Olubunmi Afonja	1
15	Human Intestinal Enteroids: New Models to Study Gastrointestinal Virus Infections 2017 ·Methods in molecular biology ·Winnie Y. Zou, Sarah E. Blutt, Sue E. Crawford, Khalil Ettayebi, Xi-Lei Zeng, Kapil Saxena, Sasirekha Ramani, Umesh C. Karandikar, Nicholas C. Zachos, Mary K. Estes	106
16	Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: The experience of the Hemostasis and Thrombosis Research Society (HTRS) Registry (2004–2008) 2013 ·Pediatric Blood & Cancer ·Ellis J. Neufeld, Kapil Saxena, Craig M. Kessler, David L. Cooper, (unknown)	7
17	40K glycoPEGylated, recombinant FVIIa: 3‐month, double‐blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors 2013 ·Journal of Thrombosis and Haemostasis ·Rolf Ljung, Faraizah Abdul Karim, Kapil Saxena, Takashi Suzuki, Per Arkhammar, Anders Rosholm, Paul Giangrande	27
18	Effect of Acute Bleeding on Daily Quality of Life Assessments in Patients with Congenital Hemophilia with Inhibitors and Their Families: Observations from the Dosing Observational Study in Hemophilia 2012 ·Value in Health ·Ellis J. Neufeld, Michael Recht, Hernan Sabio, Kapil Saxena, Caitlyn T. Solem, A. Simon Pickard, Robert Gut, David L. Cooper	51
19	Great genotypic and phenotypic diversities associated with copy-number variations of complement C4 and RP-C4-CYP21-TNX (RCCX) modules: A comparison of Asian-Indian and European American populations 2009 ·Molecular Immunology ·Kapil Saxena, Kathryn J. Kitzmiller, Yee Ling Wu, Bi Zhou, (unknown), Leena Hiremath, Erwin K. Chung, Yan Yang, C. Yung Yu	33
20	Dancing with Complement C4 and the RP-C4-CYP21-TNX (RCCX) Modules of the Major Histocompatibility Complex 2003 ·Progress in nucleic acid research and molecular biology ·C. Yung Yu, Erwin K. Chung, Yan Yang, Carol A. Blanchong, (unknown), Kapil Saxena, Zhenyu Yang, Webb Miller, Lilian Varga, George Füst	40

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact